Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Change in Account Payables (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Change in Account Payables for 11 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Account Payables rose 107.15% year-over-year to $1.4 million, compared with a TTM value of $8.2 million through Dec 2025, up 151.55%, and an annual FY2025 reading of $8.2 million, up 151.55% over the prior year.
  • Change in Account Payables was $1.4 million for Q4 2025 at Spyre Therapeutics, down from $3.7 million in the prior quarter.
  • Across five years, Change in Account Payables topped out at $17.2 million in Q3 2024 and bottomed at -$20.2 million in Q4 2024.
  • Average Change in Account Payables over 5 years is -$586050.0, with a median of -$212000.0 recorded in 2023.
  • The sharpest move saw Change in Account Payables skyrocketed 29200.0% in 2021, then tumbled 6955.4% in 2024.
  • Year by year, Change in Account Payables stood at $1.5 million in 2021, then crashed by 340.55% to -$3.5 million in 2022, then surged by 91.8% to -$287000.0 in 2023, then crashed by 6955.4% to -$20.2 million in 2024, then soared by 107.15% to $1.4 million in 2025.
  • Business Quant data shows Change in Account Payables for SYRE at $1.4 million in Q4 2025, $3.7 million in Q3 2025, and $1.1 million in Q2 2025.